Oguz Yavuzgil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Oguz Yavuzgil has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Anıl Ziya Apaydin
Department of Cardiovascular Surgery, Faculty of Medicine, Ege University, 35100 Izmir, Turkey
1 shared publication - Arafat Yildirim
Department of Cardiology, Adana Training and Research Hospital, University of Health Sciences, Adana, Turkey
1 shared publication - Emrah Oguz
Department of Cardiovascular Surgery, Faculty of Medicine, Ege University, 35100 Izmir, Turkey
1 shared publication - Hakan Posacioglu
Department of Cardiovascular Surgery, Faculty of Medicine, Ege University, 35100 Izmir, Turkey
1 shared publication - Irem Demiray
Department of Cardiovascular Surgery, Ege University Medical School, Izmir 35100, Türkiye
1 shared publication - Ismet Tanzer Calkavur
Department of Cardiovascular Surgery, Faculty of Medicine, Ege University, 35100 Izmir, Turkey
1 shared publication
Latest Publications
- Open Access
Sutureless Aortic Valve Replacement with the Perceval Plus® Versus TAVI: A Propensity-Matched Analysis of Postoperative Outcomes, Hematological Dynamics, and Inflammatory Response
Perceval Plus and TAVI are increasingly used for severe aortic stenosis, both relying on a self-expanding nitinol stent design, yet evidence specific to Perceval Plus remains limited regarding postoperative clinical outcomes and hematological and inflammatory dynamics. We compared postoperative clinical outcomes and longitudinal platelet/CRP dynamics between Perceval Plus and TAVI in a retrospective single-center cohort, in which 26 propensity score-matched pairs were obtained (1:1 matching) from patients undergoing Su-AVR (Perceval Plus, n = 53) or TAVI (self-expanding Medtronic devices, n = 101). Mortality, echocardiographic outcomes, and rates of postoperative atrial fibrillation and conduction disturbances showed no statistically significant differences between groups, while TAVI was associated with shorter ICU and hospital stay and Su-AVR required higher FFP transfusion (p = 0.016). Platelet count declined in both groups, with a deeper nadir in Su-AVR (postoperative day 3: 66% decline) versus TAVI (day 4: 27% decline), with a significant group × time interaction (p = 0.013); CRP rose in both groups but more rapidly and to a greater magnitude in Su-AVR (time and group × time interaction, both p < 0.001). Su-AVR and TAVI showed no statistically significant differences in the clinical safety outcomes assessed but differed in postoperative hematological and inflammatory magnitude, likely reflecting multifactorial procedure- and device-related mechanisms, warranting confirmation in larger, prospective, multicenter studies.
Open AccessSutureless Aortic Valve Replacement with the Perceval Plus® Versus TAVI: A Propensity-Matched Analysis of Postoperative Outcomes, Hematological Dynamics, and Inflammatory Response
Perceval Plus and TAVI are increasingly used for severe aortic stenosis, both relying on a self-expanding nitinol stent design, yet evidence specific to Perceval Plus remains limited regarding postoperative clinical outcomes and hematological and inflammatory dynamics. We compared postoperative clinical outcomes and longitudinal platelet/CRP dynamics between Perceval Plus and TAVI in a retrospective single-center cohort, in which 26 propensity score-matched pairs were obtained (1:1 matching) from patients undergoing Su-AVR (Perceval Plus, n = 53) or TAVI (self-expanding Medtronic devices, n = 101). Mortality, echocardiographic outcomes, and rates of postoperative atrial fibrillation and conduction disturbances showed no statistically significant differences between groups, while TAVI was associated with shorter ICU and hospital stay and Su-AVR required higher FFP transfusion (p = 0.016). Platelet count declined in both groups, with a deeper nadir in Su-AVR (postoperative day 3: 66% decline) versus TAVI (day 4: 27% decline), with a significant group × time interaction (p = 0.013); CRP rose in both groups but more rapidly and to a greater magnitude in Su-AVR (time and group × time interaction, both p < 0.001). Su-AVR and TAVI showed no statistically significant differences in the clinical safety outcomes assessed but differed in postoperative hematological and inflammatory magnitude, likely reflecting multifactorial procedure- and device-related mechanisms, warranting confirmation in larger, prospective, multicenter studies.
- 4 September 2020
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 37 (1) , 207-213
Are there any subclinical myocardial dysfunctions in subjects with aortic valve sclerosis? A 3D-speckle tracking echocardiography study
Aortic valve sclerosis (AVS) is defined as calcified and thickened aortic leaflets without restriction of leaflet motion. We have not found any studies that previously assessed the effect of AVS on myocardial functions with three dimensional-speckle tracking echocardiography (3D-STE). Therefore, we aimed to identify any early changes in left atrial (LA) myocardial dynamics and/or left ventricular (LV) systolic functions in patients with AVS using 3D-STE. Seventy-five patients with AVS and 80 age- and gender-matched controls were enrolled into the study. The baseline clinical characteristics of the study patients were recorded. Conventional 2D echocardiographic and 3D-STE analyses were performed. The LV-global longitudinal strain (LV-GLS) and LV-global circumferential strain (LV-GCS) were significantly decreased in the AVS (+) group than in the control group (p < 0.001 and p = 0.013, respectively). In multivariate logistic regression analysis; LV-GLS (p < 0.001, odds ratio (OR) = 3.16, 95% confidence interval (CI) 1.42–5.63) and Triglyceride (TG) (p = 0.033, OR = 1.29, 95% CI 1.11–1.72) were found to be independent predictors of AVS. ROC analysis was performed to find out the ideal LV-GLS cut-off value for predicting the AVS. A LV-GLS value of > − 18 has 85.8% sensitivity, 67.5% specificity for the prediction of the AVS. Our results support that subjects with AVS may have subclinical LV deformation abnormalities even though they have not LV pressure overload. According to our findings, patients with AVS should be investigated in terms of atherosclerotic risk factors, their dysmetabolic status should be evaluated and closely followed up for their progression to calcific aortic stenosis.
- 4 September 2020
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 37 (1) , 207-213
Are there any subclinical myocardial dysfunctions in subjects with aortic valve sclerosis? A 3D-speckle tracking echocardiography study
Aortic valve sclerosis (AVS) is defined as calcified and thickened aortic leaflets without restriction of leaflet motion. We have not found any studies that previously assessed the effect of AVS on myocardial functions with three dimensional-speckle tracking echocardiography (3D-STE). Therefore, we aimed to identify any early changes in left atrial (LA) myocardial dynamics and/or left ventricular (LV) systolic functions in patients with AVS using 3D-STE. Seventy-five patients with AVS and 80 age- and gender-matched controls were enrolled into the study. The baseline clinical characteristics of the study patients were recorded. Conventional 2D echocardiographic and 3D-STE analyses were performed. The LV-global longitudinal strain (LV-GLS) and LV-global circumferential strain (LV-GCS) were significantly decreased in the AVS (+) group than in the control group (p < 0.001 and p = 0.013, respectively). In multivariate logistic regression analysis; LV-GLS (p < 0.001, odds ratio (OR) = 3.16, 95% confidence interval (CI) 1.42–5.63) and Triglyceride (TG) (p = 0.033, OR = 1.29, 95% CI 1.11–1.72) were found to be independent predictors of AVS. ROC analysis was performed to find out the ideal LV-GLS cut-off value for predicting the AVS. A LV-GLS value of > − 18 has 85.8% sensitivity, 67.5% specificity for the prediction of the AVS. Our results support that subjects with AVS may have subclinical LV deformation abnormalities even though they have not LV pressure overload. According to our findings, patients with AVS should be investigated in terms of atherosclerotic risk factors, their dysmetabolic status should be evaluated and closely followed up for their progression to calcific aortic stenosis.
- Open Access
- 1 January 2016
- Published by Turkish Society of Cardiology in Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology
- Vol. 44 (Supp:Suppl) , 1-7
Stable coronary heart disease: Epidemiology and the current treatment guidelines
- 1 January 2016
- Published by Turkish Society of Cardiology in Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology
- Vol. 44 (Supp:Suppl) , 1-7
Open AccessStable coronary heart disease: Epidemiology and the current treatment guidelines
- 17 July 2012
- Published by Galenos Yayinevi in Turkish Journal of Thoracic and Cardiovascular Surgery
- Vol. 20 (3) , 427-433
Septal alcohol ablation in hypertrophic obstructive cardiomyopathy: A retrospective analysis
- 17 July 2012
- Published by Galenos Yayinevi in Turkish Journal of Thoracic and Cardiovascular Surgery
- Vol. 20 (3) , 427-433
Septal alcohol ablation in hypertrophic obstructive cardiomyopathy: A retrospective analysis